Drug effects on melanoma

Koomen, E.R.

Chapter 6

Non-Steroidal Anti-Inflammatory Drugs and Melanoma Risk: Large Dutch Population-Based Case–Control Study

NSAIDs and melanoma risk

6

Arjen Joosse, Els R. Koomen, Mariël K. Casparie, Ron M.C. Herings, Henk-Jan Guchelaar and Tamar Nijsten

Journal of Investigative Dermatology 2009, 129(11), 2620-2627

Abstract

Background: This case-control study investigates the potential chemoprophylactic properties of non-steroidal anti-inflammatory drugs (NSAIDs) on the incidence of cutaneous melanoma (CM).

Patients and Methods: Data were extracted from the Dutch PHARMO pharmacy database and the PALGA pathology database. Cases had a primary CM between 1991 and 2004, were ≥ 18 years and were observed for 3 years in PHARMO before diagnosis. Controls were matched for date of birth, gender and geographical region. NSAIDs and acetylsalicylic acids (ASAs) were analyzed separately. Adjusted odds ratio (OR) and 95% confidence interval (CI) were calculated using multivariable logistic regression, and results were stratified across gender.

Results: 1318 CM cases and 6786 controls were eligible to enter the study. CM incidence was not significantly associated with ever ASA use (adjusted OR = 0.92, 95% CI = 0.76-1.12) or ever non-ASA NSAID use (adjusted OR = 1.10, 95% CI = 0.97-1.24). However, continuous use of low-dose ASAs was associated with a significant reduction of CM risk in women (adjusted OR = 0.54, 95% CI = 0.30-0.99) but not in men (adjusted OR = 1.01, 95% CI = 0.69-1.47). A significant trend (p = 0.04) from no use, non-continuous use to continuous use was observed in women.

Conclusion: Continuous use of low-dose ASAs may be associated with a reduced incidence of CM in women, but not in men.

Introduction

Cutaneous melanoma (CM) is a growing health problem, as CM incidence rates are steadily rising in both Europe [1] and the United States [2]. However, mortality rates seem to have leveled off, probably caused by increased awareness resulting in early detection of CM. [3] Although local CM is generally successfully treated with surgery, for metastatic disease therapeutic results remain disappointing. [1,4] Consequently, focus of melanoma research has shifted from therapy to prevention and early detection.

Chemoprevention may complement current preventive measures and is defined as the use of natural or synthetic agents to prevent, reverse, suppress or delay premalignant lesions from progressing into invasive cancer. [5] Non-steroidal anti-inflammatory drugs (NSAIDs) have shown promising results in various solid cancers [6] and may have chemopreventive potential in CM. [7] *In vitro* studies in melanoma cell lines have shown that NSAIDs can induce apoptosis [8,9] and inhibit tumor growth and invasion. [8,10,11]

The proposed anti-cancer mechanism of NSAIDs is inhibition of cyclooxygenase-2 (COX-2). This enzyme is inducable by inflammatory stimuli, is overexpressed in different neoplasms, and is probably linked to carcinogenesis through various mechanisms, for example, angiogenesis, apoptosis, inflammation, and immune function. [6, 12] However, NSAIDs may inhibit cancer through various COX-independent pathways as well. [13,14] This could be of particular importance in CM, as NSAIDs inhibit growth of CM cell lines independent of COX-2 [8-10,12,15] and COX-2 is not consistently expressed in CM. [9,11,16-18]

Thus far, most of the epidemiological studies assessing the chemoprophylactic effects of NSAIDs on CM incidence focus on acetylsalicylic acids (ASAs). A randomized controlled trial (RCT) and a large cohort study did not find an association between low- or high-dose aspirin use and CM incidence. [19,20] Studies investigating a possible association of CM and non-ASA NSAIDs are limited. Recently, a large cohort study did not observe an association with either ASA or non-ASA NSAIDs on CM incidence. [21] However, two smaller epidemiological studies suggested a reduced risk on CM incidence and progression in NSAID users. [22,23] Therefore, the potential chemoprophylactic properties of NSAIDs remain unclear due to heterogenity in study design and conflicting results.

The objective of this study is to investigate a possible protective effect of ASA and non-ASA NSAIDs on CM incidence in a large population-based sample by linking the Dutch pathology registry with a pharmacy database.

Patients and methods

Setting

This study was designed as a case-control study, using population-based data from two Dutch databases. PHARMO is a network of linked databases including a pharmacy database containing more than 2 million Dutch residents, representing 12% of the total Dutch population. The residents were included regardless of type of insurance. [24] An individual enters the PHARMO database when obtaining the first prescription in a PHARMO pharmacy, and is observed until the last prescription. As most patients in The Netherlands visit a single pharmacy, drug-dispensing records are virtually complete. [25] The prospectively gathered computerized drug-dispensing records contain the date of dispense, type, quantity, dosage form, strength, and daily dose of the prescribed drug.

PHARMO was linked to PALGA, the Dutch registry of histo- and cytopathology, using a variation of a reliable probabilistic algorithm. PALGA contains abstracts of all Dutch pathology reports encrypted with patient identification and diagnostic terms in scope with the SNOMED classification, and reached 100% participation from 1990 onwards, and therefore is the basis of the Netherlands Cancer Registry. [26]

The protocol of this study was approved by the scientific and privacy committees of both PALGA and PHARMO, and was granted exempt status by the ethics board of the Leiden University Medical Centre.

Study population

Cases were defined as individuals with a CM diagnosis in PALGA between January 1st 1991 and December 14th 2004 and who were also registered in PHARMO in this period. The endpoint of the observation period up was defined as the date of CM diagnosis (index date). For each case, two investigators (AJ, ERK) extracted final diagnosis, date and Breslow's depth from the PALGA pathology reports with high accordance (kappa values > 0.85). [27] Cases were excluded if, in PALGA, the date of primary CM diagnosis was before the age of 18 years or before January 1st 1991, the primary melanoma was not pathologically confirmed, was *in situ*, or was non-cutaneous, or in PHARMO, the date of entry was unknown, gender was unknown, or time of observation before CM diagnosis was < 3 years (Fig. 1) .

For every eligible case, an average of five controls matched for gender, date of birth (± 2 years) and geographic region (~100 regions based on clusters of local pharmacies) was sampled from PHARMO. To calculate the time of observation for the controls, they were assigned the index date of the matched case to be able to determine the

Figure 1



1 Cases Excluded	Total	n=2243	100 %
1 = Entry date missing		n = 78	3.5 %
2 = Age at diagnosis <18 yrs		n = 19	0.8 %
3 = OP 3 yr before CM incomplete		n = 1408	63 %
4 = CM not pathologically confirmed		n = 343	15 %
5 = Primary CM before 1991		n = 93	4.1 %
6 = No Cutaneous MM (e.g. eye)		n = 205	9.1%
7 = in situ CM		n = 44	2.0%
8 = No matched controls included		n = 53	2.4 %

2 Controls Excluded	Total	n=9347	100 %
1 = Entry date missing		n = 640	6.8 %
2 = Age at diagnosis < 18 yrs		n = 30	0.3 %
3 = OP 3 yr before index date incomplete		n = 8673	93 %
4 = possible CM patient (ICD code 'CM')		n = 4	0.04 %

3 year observation period. Controls were excluded if, in PHARMO, the date of entry was unknown, they were younger than 18 years at the index date, the time of observation before index date was < 3 years, or a diagnosis of melanoma was recorded according to the International Classification of Disease (ICD9-CM) in the hospital linkage database of PHARMO (Fig. 1).

Drug Exposure

For all cases and controls, systemic NSAID use, restricted to the 3-year observation period before the index date, was extracted from the PHARMO database using the anatomical therapeutical classification (ATC) codes of the World Health Organization (WHO). All NSAIDs, including ASAs, available in The Netherlands were included (Table 1). Drug dispenses containing < 7 pills were excluded (for example, after a dental extraction), but weekly prescribed NSAIDs were included (for example, weekly pharmacy deliveries to nursery homes).

ASAs were investigated separately from non-ASA NSAIDs because, next to COX-2 inhibition, they inhibit thrombocyte aggregation, which has been linked to carcinogenesis. [28] Furthermore, ASAs are almost exclusively prescribed for long-term continuous use and not for intermittent use as an analgetic, in contrast with non-ASA NSAIDs.

ASA Use

Among all users, ASA use was categorized by prescribed dosage. Individuals who used low-dose ASA (30-100 mg daily) were categorized in continuous (that is, use of ≥ 990 U of ASA during the observation period of 3 years or 1095 days) and non-continuous users. Higher doses of ASA (≥100 mg) were dispensed far less frequently and were mostly prescribed for on-demand use, suggesting temporary use as an analgetic. It was not possible to extract continuous users from this group of high dose ASA users because of the low cumulative quantities of pills used during the observation period. Therefore, all users of high dose ASA were analyzed separately.

Non-ASA NSAID use

Non-ASA NSAIDs, such as ibuprofen and diclofenac, were prescribed irregularly, with a wide variation of daily prescribed doses, and to be used on demand. Therefore, assumptions for continuous or non-continuous use could not be made, and categorization was limited to the number of pills prescribed. For the categories of cumulative number of pills, the cutoff values were chosen to reflect levels of exposure: non-users, individuals who were likely to be exposed for < 2/3 of the observation period of 3 years (1-600 pills during 1095 days), individuals using on average more than one pill daily in 3 years (>1000 pills) and an intermediate group.

Potential confounders

Ever use of drugs related to progression and development of CM, such as statins [27] and estrogens [29], were considered possible confounders. The use of heparins,

Table 1 ATC codes and corresponding NSAID

ASAs	**ATC code**	**% of total** [1]
Acetylsalicylic acid	B01AC06 / N02BA01	22,5
Carbasalate calcium	B01AC08 / N02BA15	19,1
Total ASA use		***41.6***
Non-ASA NSAIDs	**ATC code**	**% of total** [2]
Diclofenac	M01AB05	20,5
Ibuprofen	M01AE01	14,5
Naproxen	M01AE02	10,0
Rofecoxib [3]	M01AH02	3,0
Diclofenac, combinations	M01AB55	2,5
Indometacin	M01AB01	2,3
Meloxicam	M01AC06	1,6
Piroxicam	M01AC01	1,2
Nabumetone	M01AX01	1,0
Ketoprofen	M01AE03	0,4
Celecoxib	M01AH01	0,3
Sulindac	M01AB02	0,3
Tiaprofenic acid	M01AE11	0,2
Aceclofenac	M01AB16	0,1
Etoricoxib	M01AH05	0,1
Flurbiprofen	M01AE09	0,1
Tenoxicam	M01AC02	0,1
Dexibuprofen	M01AE14	<0,1
Dexketoprofen	M01AE17	<0,1
Diflunisal	N02BA11	<0,1
Tolfenamic acid	M01AG02	<0,1
Metamizole sodium	N02BB02	<0,1
Total Non ASA NSAID use		***58.4***

[1] All available NSAID ATC codes were included in the study. Presented are ATC codes corresponding with 1 or more prescription among cases and controls.
[2] Percentage of the total 22,279 prescriptions among cases and controls.
[3] Withdrawn from the Dutch market in 2004.

ASAs = Acetylsalicylic acids; ATC = anatomical therapeutic chemical classification system; NSAIDs = non-steroidal anti-inflammatory drugs.

Table 2 Study Group Characteristics

		Total Group			Males			Females		
		Cases n = 1318	Controls n = 6786	p-value	Cases n = 540	Controls n = 2714	p-value	Cases n = 778	Controls n = 4072	p-value
Gender [1]	male	540 (41.0%)	2714 (40.0%)							
	female	778 (59.0%)	4072 (60.0%)	0.51						
Age at index date [2]	yrs	55.3 (± 15.9)	55.9 (± 15.5)	0.18	57.7 (± 14.6)	58.0 (± 14.2)	0.72	53.6 (± 16.5)	54.6 (± 16.1)	0.13
Total unique diagnoses [2]	no.	0.71 (± 1.52)	0.61 (± 1.55)	0.04	0.84 (± 1.8)	0.66 (± 1.6)	0.02 [3]	0.62 (± 1.3)	0.59 (± 1.5)	0.55 [3]
Total unique medications [2]	no.	7.53 (± 6.49)	6.93 (± 6.78)	<0.01	6.95 (± 6.9)	6.24 (± 6.3)	0.03 [3]	7.93 (± 6.2)	7.39 (± 7.0)	0.03 [3]
Estrogen use [1]	Ever Use	246 (18.7%)	1009 (14.9%)		-	-		246 (31.6%)	1009 (24.8%)	
	Never Use	1072 (81.3%)	5777 (85.1%)	<0.01	-	-		532 (68.4%)	3063 (75.2%)	<0.01
Statin use [1]	Ever Use	115 (8.7%)	574 (8.5%)		75 (13.9%)	309 (11.4%)		40 (5.1%)	265 (6.5%)	
	Never Use	1203 (91.3%)	6212 (91.5%)	0.75	465 (86.1%)	2405 (88.6%)	0.10	738 (94.9%)	3807 (93.5%)	0.15
ASA use	Never Use	1137 (86.3%)	5853 (86.3%)		435 (80.6%)	2219 (81.8%)		702 (90.2%)	3634 (89.2%)	
	Ever Use	181 (13.7%)	933 (13.7%)	0.99	105 (19.4%)	495 (18.2%)	0.51	76 (9.8%)	438 (10.8%)	0.41
Type of ASA use	Never use	1137 (86.3%)	5853 (86.3%)		435 (80.6%)	2219 (81.8%)		702 (90.2%)	3634 (89.2%)	
	Low-dose non-continuous	76 (5.8%)	455 (6.7%	0.24	42 (7.8%)	239 (8.8%)	0.53	34 (4.4%)	216 (5.3%)	0.28
	Low-dose continuous	61 (4.6%)	329 (4.8%)	0.75	48 (8.9%)	204 (7.5%)	0.28	13 (1.7%)	125 (3.1%)	0.03
	High dose	44 (3.3%)	149 (2.2%)	0.02	15 (2.8%)	52 (1.9%)	0.19	29 (3.7%)	97 (2.4%)	0.04
Non-ASA NSAIDs use	Never Use	700 (53.1%)	3862 (56.9%)		304 (56.3%)	1598 (58.9%)		396 (50.9%)	2264 (55.6%)	
	Ever Use	618 (46.9%)	2924 (43.1%)	0.01	236 (43.7%)	1116(41.1%)	0.27	382 (49.1%)	1808 (44.4%)	0.02

Cumulative nr. of pills	No use	700 (53.1%)	3862 (56.9%)		304 (56.3%)	1598 (58.9%)		396 (50.9%)	2264 (55.6%)		
	1-600	588 (44.6%)	2728 (40.2%)	<0.01	226 (41.9%)	1051 (38.7%)	0.20	362 (46.5%)	1677 (41.2%)	<0.01	
	601-1000	12 (0.9%0	92 (1.4%)	0.29	3 (0.6%)	31 (1.1%)	0.26	9 (1.2%)	61 (1.5%)	0.63	
	>1000	18 (1.4%)	104 (1.5%)	0.86	7 (1.4%)	34 (1.3%)	0.85	11 (1.4%)	70 (1.7%)	0.74	

[1] Number of cases and controls presented, ± SD tested for statistical difference with χ^2-test.
[2] Mean value presented, tested for statistical difference with t-test
[3] Equal variances not assumed according to Levene's test for Equality of variances

ASA = acetylsalicylic acid, NSAIDs = non-steroidal anti-inflammatory drugs.

fibrates, and other llipid-lowering drugs was also recorded. However, the number of individuals using these drugs was too small (<1.0%) to be used in further analysis. To adjust for a possible surveillance bias (that is, patients who seek medical care are more likely to be diagnosed with other disease including CM), a proxy of health-care and pharmacy-seeking behaviour was created by calculating the total number of unique ATC codes (excluding all NSAIDs) and the total number of unique ICD9-CM codes (that were primary discharge diagnosis after hospitalization) which were both recorded in the database in the 3 years before the index date. The ICD code for melanoma found for each case was not included in the total number of unique ICD codes to avoid overmatching. Both confounders proved to be significant in all multivariable analyses performed and also showed a significant interaction with each other. This interaction term was added in the multivariable analysis (p <0.01).

Statistical Analysis

A chi-square test was used to test for statistical differences between categorical variables, for continuous variables a Student's *t*-test or a Mann-Whitney U test was used as appropriate. A multivariable logistic regression model was used to calculate adjusted odds ratios (OR) and 95% confidence intervals (CI) to analyze the association between dependent CM incidence and NSAID use and its defined categorizations of exposure.

As CM development, progression and survival, as the effect of potential chemoprophylactic drugs, may differ across gender [27,28,30,31], a pre-specified separate analysis for men, women and the total group was carried out.

All statistical tests were two sided, with a rejection of the null hypothesis at p <0.05. All statistical analyses were performed using SPSS 14.0 (.2) (SPSS Inc. Chicago, IL).

Results

Study population

The ascertainment of the cases and controls has been described previously. [27] Briefly, of the 3561 subjects who were registered in PHARMO (Institute for Drug Outcome Research) and had a systemized nomenclature of medicine (SNOMED) code 'melanoma' in PALGA (the natoinwide network and registry of histo- and cytopathology in The Netherlands), 1318 cases (37.0%) met the eligibility criteria (Fig. 1). Patients were mostly excluded because the registration periods in PHARMO and PALGA did not match, leading to incomplete pharmacy records in PHARMO in the 3-year observation period before CM diagnosis. Of the 16133 controls matched on gender, age and geographical region, 6786 (42.1%) met the inclusion criteria.

About 60% of the study population was female, with a mean age of 55 years (Table 2). Compared with the controls, cases had a significantly higher number of unique non-melanoma international classification of disease (ICD) diagnoses (0.71 versus 0.61, $p = 0.04$), which was confirmed in men, but not in women. Also, cases had a higher number of unique medications prescribed (7.53 unique ATC codes versus 6.93, $p < 0.01$), which was confirmed in both men and women. As reported earlier, women with melanoma used more estrogens compared to the control population (31.6% versus 24.8%, $p < 0.001$). [29]

ASA use and CM incidence

More than 40% of the total NSAID use consisted of ASA use (Table 1). The proportion of CM patients who used ASA was comparable to the controls, except for high dose ASAs (Table 2). Female cases were significantly less likely to be a continuous user of low-dose ASAs than their matched controls (1.7% versus 3.1%, $p = 0.03$). In men, no significant difference in the distribution of ASA exposure was observed. After adjusting for age, gender, year of diagnosis, prior use of statins and estrogens, and unique number of ICD and ATC codes in a multivariable model, none of the ASA exposure variables was significantly associated with CM incidence in the total study population and in men (Table 3). However, in women, continuous use of low-dose ASA for 3 years was associated with a reduced risk of developing a CM of almost 50% (adjusted OR = 0.54, 95% CI = 0.30-0.99). In addition, in women, there was a significant dose-response trend for no use, non-continuous use, and continuous use (p-value for trend=0.04).

Table 3 ASA / NSAID use and cutaneous melanoma

		Total			Males			Females		
		n	*Adjusted OR*[†]	*95% CI*	*n*	*Adjusted OR*[†]	*95% CI*	*n*	*Adjusted OR*[†]	*95% CI*
ASA use	*Overall Exposure*									
	Never ASA use	6990	1.00	*referent*	2654	1.00	*referent*	4336	1.00	*referent*
	ASA use	1114	0.92	0.76-1.12	600	0.92	0.69-1.21	514	0.90	0.68-1.19
	Use of ASA									
	Never Use	6990	1.00	*referent*	2654	1.00	Referent	4336	1.00	*referent*
	Low dose < 3 yrs [1]	531	0.77	0.58-1.01	281	0.72	0.49-1.06	250	0.82	0.55-1.22
	Low Dose 3 yrs [1]	390	0.87	0.64-1.18	252	1.01	0.69-1.47	138	**0.54**	**0.30-0.99**
	High dose (ever) [2]	193	1.35	0.96-1.92	67	1.34	0.74-2.43	126	1.37	0.89-2.11
Non-ASA NSAIDs	*Overall Exposure*									
	Never NSAID use	4562	1.00	*referent*	1902	1.00	*referent*	2660	1.00	*referent*
	NSAID use	3542	1.10	0.97-1.24	1352	1.04	0.86-1.26	2190	1.13	0.96-1.34
	Cumulative Pills									
	0	4562	1.00	*referent*	1902	1.00	*referent*	2660	1.00	*referent*
	1-600	3316	1.12	0.98-1.23	1277	1.06	0.87-1.27	2039	1.15	0.98-1.36
	601-1000	104	0.67	0.36-1.23	34	0.46	0.14-1.51	70	0.82	0.40-1.69
	>1000	122	0.89	0.53-1.43	41	0.96	0.42-2.21	81	0.88	0.46-1.69

[1] Adjusted for age, sex (only in total group), year of diagnosis, the use of statins resp. estrogens (only in females), the total of different medical diagnoses, total of different medications prescribed and the interaction term between the latter two.
[2] use of 30-100 milligrams acetylsalicylic acid per unit (≥ 990 pills is considered 3 years –continuous- use).
[3] use of >100 milligrams acetylsalicylic acid per unit.

OR = odd ratio, CI = confidence interval, ASA = acetylsalicylic acid, NSAIDs = non-steroidal anti-inflammatory drugs.

Non-ASA NSAID use and CM incidence

The most commonly dispensed non-ASA NSAIDs were diclofenac (20,5%), ibuprofen (14,5%) and naproxen (10.0%) (Table 1). Female and, to a lesser extent, male CM patients were more likely to have ever used non-ASA NSAIDs compared to controls (Table 2). Of the non-ASA NSAID users, the overwhelming majority used < 600 pills during 3 years and only 2.3% and 2.9% of cases and controls, respectively, used more than 600 pills. In the distribution of the categories of the cumulative number of pills, the only significant difference was observed in the lowest category of 1-600 pills for the total study population and women.

In the multivariable models that adjusted for multiple confounders, no significant associations were found, although relative low non-ASA NSAID exposure (1-600 pills) was borderline significantly associated with a modest increase in CM risk (OR = 1.12, 95% CI = 0.98-1.23, Table 3). In further subgroup analysis, the use of 1-4 prescriptions of non-ASA NSAIDs in 3 years was significantly associated with a marginally increased risk of CM (OR = 1.15, 95% CI = 1.01-1.30, data not shown). Higher levels of exposure appeared to be protective for all subgroups, but none of these associations were significant (Table 3).

Discussion

NSAID use and risk of CM

Continuous use of low-dose ASAs during 3 years was associated with a reduced likelihood of developing CM in women but not in men.

In contrast, none of the non-ASA NSAID variables were significantly associated with risk of having a CM in the multivariable model (Table 3). However, infrequent use of pills (1-600 pills in 3 years), was significantly associated with the incidence of CM in univariate analysis (Table 2), but this was not significant in the multivariable model after adjusting for health-care consumption (Table 3), suggesting that this and possibly other confounders affected the univiarate model. Interestingly, a similar association has been reported in a case-control study in prostate cancer. [33] This illustrates that health care utilization may be an important confounder in pharmaco-epidemiological studies.

The use of larger quantities of non-ASA NSAIDs (>600 pills in 3 years) seemed to be protective for CM but did not reach significance, which could be explained, in part, by a relatively short time of observation (3 years), limited sample size in this subgroup (<225 patients), and/or that non-ASA NSAIDs were administered as analgetics (the

prescribed frequency of use by physicians was most often 'when needed'); thus implying non-continuous exposure. On account of small numbers, separate analyses for selective-COX-2 inhibitors could not be carried out.

The observed difference in chemoprophylactic effects between non-ASA NSAIDs and ASAs may be dependent on the patterns of use or on a different mechanism of action. First, low-dose ASAs are most commonly prescribed as daily cardiovascular preventive drugs, whereas non-ASA NSAIDs and high dose ASAs are commonly used irregularly as analgetics. Second, ASAs may have additional anti-cancer effects in comparison to non-ASAs, such as inhibition of thrombocyte-aggregation [28], or effects cancer-related systems as apoptosis, NF-κB, DNA-repair systems, oxidative stress, or mitochondrial calcium uptake. [14]

We did not find a reduced CM incidence among overall non-ASA NSAID or ASA users, which is in accordance with three large observational studies. A large cohort study of regular and high dose ASA (>325 mg) exposure observed no protective effect on CM. [20] A second cohort confirmed the absence of an association between ASA or non-ASA NSAID use and CM incidence. [21] This study, however, has several limitations, that is, low-dose aspirin exposure was excluded in subgroup analyses, ~40% of cases were CM *in situ*, and stratification across gender was not carried out. Our results, showing an association of low-dose ASA use in women with CM is in contrast with an RCT among females for whom low-dose aspirin use (100 mg every other day) for an average of 10 years did not affect CM incidence (68 versus 70 incident cases, $p = 0.87$). [19] This study however was limited by a small number of CM cases, non-continuous exposure, and was not population-based.

In other malignancies, multiple studies investigating the chemopreventive properties of ASA and non-ASA NSAIDs have been published. A review showed that in colorectal, breast and lung cancer, the risk reductions by non-ASA NSAIDs and ASAs were comparable [6], which contradicts our results that suggest a different effect. Results of a case-control study on prostate cancer, however, were comparable: prolonged use of ASAs showed a protective effect, whereas use of non-ASA NSAIDs did not. [33] In lung [34], breast [35] and prostate [33] cancer, exposure to regular or high-dose use of ASAs did, but exposure to low-dose ASA did not, decrease the incidence of these cancers, which is not in line with our findings in CM patients.

However, comparing the results of studies assessing the chemoprophylactic effect of NSAIDs is challenging because studies differ in several important ways such as ascertainment of drug exposure (for example, self-reported or pharmacy database), definition of exposure, type of NSAID (ASA or non-ASA), dose, duration, patterns of use (for example, sporadic, intermittent, chronic), drug adherence, study population (for example, general population, cohorts from tertiary centers), melanoma (for example, invasive or *in situ* CM), sample size, and subgroup analyses (that is, stratification across gender). A pivotal unresolved problem is the definition of the dosage of NSAID, which could have chemoprophylactic effects.

Gender differences

Stratification across gender showed a gender difference in favor of women, especially for continuous use of low-dose ASAs. This apparent discrepancy between men and women is not well understood and may be explained by pharmacological and melanoma differences. Pharmacodynamics and pharmacokinetics of ASA differ between men and women: the effect on platelets differs across gender and women achieve higher concentrations with equal doses being administrated. [32] As ASA may influence oxidative stress, the gender difference in antioxidant enzymes may have a role. [36] Remarkably, a recent RCT investigating antioxidant supplementation showed an increase of CM incidence in women, but not in men. [37] Another explanation may be that melanoma biology itself may not be comparable in men and women, as CM survival differs significantly across gender when adjusted for other prognostic factors. [30,31] Differences in adherence to cardiovascular drugs, however, are not likely to explain the observed gender differences. [38]

Interestingly, we previously reported a gender difference in the effects of statins on CM incidence and progression using the same study population. [27] Future (epidemiological) studies are warranted to explore CM gender differences.

Strengths and weaknesses

This is the largest population-based study that investigates the effect of NSAID use on CM incidence in more than 1350 cases. The CM cases were confirmed by a pathology report, and drug exposure was prospectively assessed by a highly reliable pharmacy database. [39] In PHARMO, detailed information on drug use was available, such as the number of dispenses, the number of dispensed pills, and dosage. As the dosages (in WHO's defined daily doses) of NSAIDs differ largely between the indications for which they are prescribed, we were not able to include this information. Furthermore, since a large proportion of the NSAIDs are used as analgetics 'on demand', no data were

available regarding the duration of use for these types of NSAIDs. Therefore, duration of use could not be included in the analyses, except based on the number of pills prescribed. As several NSAIDs are available over the counter without a prescription, the actual use of NSAIDs is underestimated. Therefore, if this would influence our results, it is most likely that this would produce bias toward the null. However, this misclassification is likely to be equal among cases and controls; hence, bias is likely to be minimal. In this study, NSAID use was ascertained in the 3 years before CM diagnosis, which may have been too short to detect the effect of NSAID exposure. [6] However, increasing the observation period to 5 years decreased the sample size substantially (from 1318 to 931 CM cases). Although a proxy for health care consumption was included in the multivariable model, surveillance bias may still have affected our results. Information on life-style factors such as sun exposure was not available, but the confounding effect of sun exposure on NSAID use seems to be limited.

Conclusion

In conclusion, long-term use of (low-dose) ASA was associated with a reduced risk of CM in women, but not in men. Future observational and ultimately interventional clinical studies are needed to confirm these findings.

Acknowledgements

We thank Prof. Jan Vandenbroucke for critical discussion of the design of the study and Dr Mark Tinga for data selection in PHARMO RLS Network.

Reference List

(1) de Vries E, Bray FI, Coebergh JW, Parkin DM. Changing epidemiology of malignant cutaneous melanoma in Europe 1953-1997, rising trends in incidence and mortality but recent stabilizations in western Europe and decreases in Scandinavia. Int J Cancer 2003, 107, 119-126.

(2) http,//www.cancer.org, Cancer facts and Figures 2007, last visited on January 5th 2009.

(3) de Vries E, Coebergh JW. Cutaneous malignant melanoma in Europe. Eur J Cancer 2004, 40, 2355-2366.

(4) Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma, a systematic review of 41 randomised clinical trials. Lancet Oncol 2003, 4, 748-759.

(5) Demierre MF. What about chemoprevention for melanoma? Curr Opin Oncol 2006, 18, 180-184.

(6) Harris RE, Beebe-Donk J, Doss H, Burr Doss D. Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention, a critical review of non-selective COX-2 blockade (review). Oncol Rep 2005, 13, 559-583.

(7) Francis SO, Mahlberg MJ, Johnson KR, Ming ME, Dellavalle RP. Melanoma chemoprevention. J Am Acad Dermatol 2006, 55, 849-861.

(8) Bundscherer A, Hafner C, Maisch T, Becker B, Landthaler M, Vogt T. Antiproliferative and proapoptotic effects of rapamycin and celecoxib in malignant melanoma cell lines. Oncol Rep 2008, 19, 547-553.

(9) Vogt T, McClelland M, Jung B, Popova S, Bogenrieder T, Becker B, *et al.* Progression and NSAID-induced apoptosis in malignant melanomas are independent of cyclooxygenase II. Melanoma Res 2001, 11,587-599.

(10) Chiu LC, Tong KF, Ooi VE. Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells. Biomed Pharmacother 2005, 59 Suppl 2, S293-297.

(11) Denkert C, Kobel M, Berger S, Siegert A, Leclere A, Trefzer U, *et al.* Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res 2001, 61, 303-308.

(12) Xu XC. COX-2 inhibitors in cancer treatment and prevention, a recent development. Anticancer Drugs 2002, 13, 127-137.

(13) Marx J. Cancer research. Anti-inflammatories inhibit cancer growth--but how? Science 2001, 291, 581-582.

(14) Elwood PC, Gallagher AM, Duthie GG, Mur LA, Morgan G. Aspirin, salicylates and cancer. Lancet 2009, 373, 1301-1309.

(15) Lee C, Ramirez JA, Guitart J, Diaz LK. Expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma during malignant melanoma progression. J Cutan Pathol 2008, 35, 989-994.

(16) Goulet AC, Einsphar JG, Alberts DS, Beas A, Burk C, Bhattacharyya A, *et al.* Analysis of cyclooxygenase 2 (COX-2) expression during malignant melanoma progression. Cancer Biol Ther 2003, 2, 713-718.

(17) Kuzbicki L, Sarnecka A, Chwirot BW. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression. Melanoma Res 2006, 16, 29-36.

(18) Nettelbeck DM, Rivera AA, Davydova J, Dieckmann D, Yamamoto M, Curiel DT. Cyclooxygenase-2 promoter for tumor-specific targeting of adenoviral vectors to melanoma. Melanoma Res 2003, 13,287-292.

(19) Cook NR, Lee IM, Gaziano JM, Gordon D, Ridker PM, Manson JE, *et al.* Low-dose aspirin in the primary prevention of cancer, the Women's Health Study, a randomized controlled trial. Jama 2005, 294, 47-55.

(20) Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst 2007, 99, 608-615.

(21) Asgari MM, Maruti SS, White E. A large cohort study of nonsteroidal anti-inflammatory drug use and melanoma incidence. J Natl Cancer Inst 2008, 100, 967-971.

(22) Harris RE, Beebe-Donk J, Namboodiri KK. Inverse association of non-steroidal anti-inflammatory drugs and malignant melanoma among women. Oncol Rep 2001, 8, 655-657.

(23) Ramirez CC, Ma F, Federman DG, Kirsner RS. Use of cyclooxygenase inhibitors and risk of melanoma in high-risk patients. Dermatol Surg 2005, 31,748-752.

(24) http,//www.pharmo.nl/, PHARMO RLS Network, last visited January 5th 2009.

(25) Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997, 50, 619-625.

(26) Casparie M, Tiebosch AT, Burger G, Blauwgeers H, van de Pol A, van Krieken JH, *et al.* Pathology databanking and biobanking in The Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology data network and archive. Cell Oncol 2007, 29,19-24.

(27) Koomen ER, Joosse A, Herings RM, Casparie MK, Bergman W, Nijsten T, *et al.* Is statin use associated with a reduced incidence, a reduced Breslow thickness or delayed metastasis of melanoma of the skin? Eur J Cancer 2007, 43, 2580-2589.

(28) Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res 2001, 102, V215-224.

(29) de Vries E, Nijsten TE, Visser O, Bastiaannet E, van Hattem S, Janssen-Heijnen ML, *et al.* Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol 2008, 19, 583-589.

(30) Lasithiotakis K, Leiter U, Meier F, Eigentler T, Metzler G, Moehrle M, *et al.* Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer 2008, 112, 1795-1804.

(31) Levin RI. The puzzle of aspirin and sex. N Engl J Med 2005, 352, 1366-1368.

(32) Koomen ER, Joosse A, Herings RM, Casparie MK, Guchelaar HJ, Nijsten T. Estrogens, oral contraceptives and hormonal replacement therapy increase the incidence of cutaneous melanoma, a population-based case-control study. Ann Oncol 2009, 20, 358-364.

(33) Perron L, Bairati I, Moore L, Meyer F. Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer 2003, 106, 409-415.

(34) Harris RE, Beebe-Donk J, Schuller HM. Chemoprevention of lung cancer by non-steroidal anti-inflammatory drugs among cigarette smokers. Oncol Rep 2002, 9, 693-695.

(35) Harris RE, Beebe-Donk J, Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006, 6, 27.

(36) May RC. Gender, immunity and the regulation of longevity. Bioassays 2007, 29, 795-802.

(37) Hercberg S, Ezzedine K, Guinot C, Preziosi P, Galan P, Bertrais S, *et al.* Antioxidant supplementation increases the risk of skin cancers in women but not in men. J Nutr 2007, 137, 2098-2105.

(38) Kulkarni SP, Alexander KP, Lytle B, Heiss G, Peterson ED. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006, 151, 185-191.

(39) Herings RMC. Pharmo, A record linkage system for postmarketing surveillance of prescription drugs in the Netherlands. Thesis in pharmacoepidemiology and pharmacotherapy. 1993, Utrecht University.